Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
A clinical trial study investigating the genetic hallmarks of patients with congenital portosystemic shunts and portopulmonary hypertension;…
-
FDA approval · 2026-01-18FDA Approved: AMBRISENTAN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ambrisentan submitted by Sun Pharmaceutical Industries, Inc. This marks an approved modifica…
-
EMA approval · 2026-01-06EMA Authorised: Talmanco (previously Tadalafil Generics) (tadalafil) — Viatris Limited
Talmanco has been authorised in the EU as a generic tadalafil product with indications in hypertension and pulmonary arterial hypertension, …
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults [Phase 1]
Phase 1 study evaluating safety, tolerability, and pharmacokinetics of the investigational drug L608 in healthy adults; the trial lists Pulm…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
This is a prospective longitudinal observational cohort study of pregnant women living at high altitude in Bolivia, sponsored by Massachuset…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-12-29FDA Approved: EPOPROSTENOL — Original Application (Gland Pharma Limited)
FDA approved Gland Pharma Limited's epoprostenol under Original Application (ANDA 219237). The drug is indicated for the treatment of pulmon…
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants [Phase 2]
This update reports that the Phase 2 extension study of LTP001 in pulmonary arterial hypertension has been terminated. Results from the term…
-
EMA approval · 2025-12-19EMA Authorised: Macitentan Accord (macitentan) — Accord Healthcare
The EMA authorised Macitentan Accord for treatment of pulmonary arterial hypertension; the marketing authorisation holder is Accord Healthca…
-
EMA approval · 2025-12-19EMA Authorised: Macitentan AccordPharma (macitentan) — Accord Healthcare
The EMA authorised Macitentan AccordPharma (macitentan) for the treatment of pulmonary hypertension, including pulmonary arterial hypertensi…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 trial update indicates empagliflozin is being studied to improve right ventricular function in pulmonary arterial hypertension and…
-
EMA approval · 2025-12-16EMA Authorised: Ambrisentan Viatris (previously Ambrisentan Mylan) (ambrisentan) — Viatris Limited
The EMA authorised Ambrisentan Viatris (ambrisentan) for pulmonary arterial hypertension, with Viatris Limited as the marketing authorisatio…
-
EMA approval · 2025-12-16EMA Authorised: Ventavis (iloprost) — Bayer AG
The European Medicines Agency authorised Ventavis (iloprost) by Bayer AG for pulmonary arterial hypertension, marking formal EU marketing ap…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study
Completed clinical trial evaluating the Venous Excess Ultrasound Score (VExUS) as part of haemodynamic risk assessment in pulmonary arterial…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD) [NA]
A completed University of Zurich study compared exercise performance in pulmonary vascular disease patients when breathing ambient air versu…
-
CLINICAL_TRIALS other · 2025-12-09Clinical Trial Update: A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension [Phase 4]
Phase 4 clinical trial investigating a mean pulmonary artery pressure-targeted approach with early Treprostinil therapy to reverse right ven…
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) [Phase 2]
Merck's sotatercept (MK-7962) completed a Phase 2 trial investigating its use in pulmonary arterial hypertension (PAH).
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 clinical trial (SIRIUS) will evaluate an initial triple therapy—an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor…
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) [Phase 2]
Phase 2 clinical study update for sotatercept (MK-7962) in pulmonary arterial hypertension; the LIGHTRAY EXTENSION study is currently active…
-
EMA approval · 2025-12-03EMA Authorised: Adempas (riociguat) — Bayer AG
EMA authorised Adempas (riociguat) by Bayer AG for pulmonary hypertension indications, with a decision dated 06/08/2025.
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension [Phase 2]
A Phase 2 trial evaluating treprostinil for interstitial lung disease-associated pulmonary hypertension has completed and posted results.
-
EMA approval · 2025-12-02EMA Authorised: Mysildecard (sildenafil) — Viatris Limited
The European Medicines Agency authorised Mysildecard (sildenafil) for indications related to hypertension and pulmonary hypertension, with V…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension [NA]
A clinical trial is investigating circulating activin-A and FSTL3 in precapillary pulmonary hypertension. The study is currently active but …
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities [Phase 3]
Phase 3 clinical trial entry comparing initial dual oral therapy versus monotherapy for pulmonary arterial hypertension with cardiovascular …
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: European Registry of Acutely Decompensated Pulmonary Arterial Hypertension
This document describes a European registry study on acutely decompensated pulmonary arterial hypertension and related pulmonary hypertensio…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases
A completed clinical trial update describing development of a new tool to measure dyspnea across chronic respiratory diseases.